Subjects must have measurable or evaluable disease:\r\n* Evaluable disease must be evidenced by computed tomography (CT) or positron emission tomography (PET) scans (abnormal PET scans may be used as long as the CT portion is of diagnostic quality)\r\n* Subject must have at least one objective measurable disease parameter:\r\n** Measurable disease on cross sectional imaging that is >=  cm in the longest diameter and measurable in  perpendicular dimensions\r\n** Splenomegaly >  cm in cranio-caudal dimension as measured by CT
Measurable disease sites on CT scan (>. cm in longest dimension)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that is:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= . cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) and/or\r\n* A malignant lymph node is considered measurable if its short axis is > . cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than  mm)\r\n* Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?  lesion that measures > . cm in the longest dimension and ? . cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.
Subject has measurable disease on cross-sectional imaging by computed tomography (CT) with at least one (post-biopsy) measurable lesion ? . cm in its longest dimension.
Patients with measurable disease defined as at least one of the following:\r\n* For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >=  cm; skin lesions can be used if the area is >=  cm in at least one diameter and measured with a ruler\r\n* Plasma cell count >= . X ^/L or  percent of the peripheral blood white cells\r\n* Plasma cell count if determined by flow cytometry, >= /, events
Measurable disease that has not been previously irradiated on computed tomography (CT) scans of at least  cm, OR if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; imaging must be completed no greater than  weeks prior to study enrollment
Participants must have measurable disease, defined as lymphocytosis >= ,/ul, or at least one palpable or CT measurable lesion > approximately . cm, or bone marrow involvement > approximately %
Have measurable disease based on defined as at least one lesion that can be accurately measured in at least two dimensions with a spiral computed tomography (CT) scan, positron emission tomography (PET)/CT scan, or magnetic resonance imaging (MRI). Minimum measurement of > . cm in longest diameter by > . cm in short axis.
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? non-biopsied, non-irradiated lesion that measures ?. cm in the longest dimension [LD] and ?. cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).
Measurable Disease\r\n* Patients must have measurable disease per RECIST . by computer tomography (CT) scan or magnetic resonance imaging (MRI)\r\n* Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >=  cm with CT or MRI (or >= . cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
Measurable disease that can be accurately measured in at least one dimension as >= . cm with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques; extranodal disease that is measurable by fludeoxyglucose F- (FDG)-positron emission tomography (PET) imaging only will also be allowed; note that if an excisional biopsy was performed that removed the sole site of measurable disease, the patient will not be eligible for leukapheresis and generation of CAR T cell product
All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is >= . cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT
Patients must have received at least  months of ibrutinib therapy and have measurable CLL by at least one of the following: Absolute monoclonal lymphocyte count > /microL; OR measurable lymph nodes with at least one node > . cm in diameter on computed tomography (CT); OR Bone marrow with >= % lymphocytes or peripheral blood specimen taken within the  months prior to starting ibrutinib or at some time during their ibrutinib therapy and analyzed at a CLIA-accredited laboratory
Measurable disease: subjects must have at least one lesion that is >  mm (. cm) in the longest diameter on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
Measurable nodal disease by computed tomography (CT)
At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= . cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= . cm when assessed by CT scan)\r\n* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease
For diseases other than CLL, LPL, and HCL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >=  lesion that measures >= . cm in the longest dimension [LD] and >= . cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measureable disease will be defined as serum monoclonal IgM > . g/dL or meeting at least  of the recommendations from the Second International Workshop on LPL for requiring treatment
Patients should have measurable metastatic disease in the liver, defined (for the purpose of this study) as at least  measurable lesion more than  cm in size and readily accessible to ultrasound (US) or computed tomography (CT)-guided biopsy
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > . cm in size or assessable disease
For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? lesion that measures ?. cm in the longest dimension [LD] and ?. cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT]).
Disease that is measurable where:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= . cm with chest x-ray, or as >= . cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)\r\n* A malignant lymph node is considered measurable if its short axis is >= . cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than  mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
Presence of measurable disease by computed tomography (CT) scan
Measurable disease as defined by at least one tumor that is measurable in two dimensions on CT or magnetic resonance imaging (MRI) scan (minimum size . cm for at least one lesion)
Patient must have measurable disease\r\n* Tumor size at least >=  cm in the longest diameter as measured by computed tomography (CT) scan or magnetic resonance imaging (MRI) for which radiation is feasible
Patients should have bi-dimensional measurable disease using the Cheson criteria (measureable disease by computed tomography [CT] scan defined as at least  lesion that measures >= . cm in single dimension)
Patients must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than . cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI), and are not included in any prior field of radiation given to treat B-NHL\r\n* In patients with CLL, circulating lymphocytes >= , / mm^\r\n* In patients with WM/LPL, measurable serum monoclonal immunoglobulin M (IgM)
Patients must have primary tumor =<  cm as defined by computed tomography (CT) largest axial dimension
Measurable disease by CT or magnetic resonance imaging (MRI) or the CT portion of the PET/CT: must have at least one lesion that has a single diameter of >=  cm
Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of  cm or greater; or palpable lesions with both diameters >=  cm; further, at least  of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of  or more); Note: CT scans remain the standard for evaluation of nodal disease
Patients must have measurable disease defined as lesions greater than . cm that can be accurately measured in two dimensions by CT (preferred), or MRI
Measurable or assessable disease is required; measurable tumor size (at least one node measuring . cm^ in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam
History of uveal melanoma and documented metastatic disease with at least one measurable lesion is required; which is >=  cm x  cm (on spiral computed tomography [CT] or equivalent)
Must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than . cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI)
Measurable disease:\r\n* For nodal or extranodal disease (lymphoma or breast): must have at least  lesions that are >=  mm (. cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT), that are amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)\r\n* For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than  cm and are amenable to intralesional injection
Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) (dedicated CT or the CT portion of a positron emission tomography [PET]/CT) or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of >= . cm \r\n* NOTE: Skin lesions can be used if the area is >= . cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
Ann-Arbor Stage  (non-contiguous), , or  disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?  lesion that measures ? . cm in the longest dimension (LD) and ? . cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomography-computed tomography (PET-CT), computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease with a lymph node or tumor mass >. cm in at least one dimension as assessed by computed tomography (CT)
Patients must have measurable disease, defined as at least one lesion that is ?  mm (? . cm) in the longest axis on cross-sectional imaging and measurable in two perpendicular dimensions per spiral computed tomography (CT) scan or positron-emission tomography (PET)-CT scan
Measurable disease defined as:\r\n* Computed tomography (CT)/magnetic resonance imaging (MRI)/ or positron emission tomography (PET) scan, with at least one nodal site of disease which is . cm in longest dimension, and/or spleen >  cm in vertical length, and/or diffuse enlargement of liver with or without focal nodules (Lugano ); extra nodal sites with biopsy proven abnormal lesions are allowed including skin\r\n* Patients with only bone marrow involvement will be acceptable
For diseases other than LPL and CLL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >=  lesion that measures >= . cm in the longest dimension [LD] and >= . cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measurable disease will be defined as serum monoclonal IgM > . g/dL or meeting at least  of the recommendations from the Second International Workshop on LPL for requiring treatment
Patients should in general have bi-dimensional measurable disease using the Cheson criteria (measurable disease by computed tomography [CT] scan defined as at least  lesion that measures >= . cm in single dimension) (bone marrow or gastrointestinal [GI] only involvement is acceptable).
Melanoma cohort only: measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= . cm with chest x-ray, or as >= . cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT; NOTE: disease that is measurable by physical examination only is not eligible
Gynecologic cancer cohort only: measureable disease, defined as at least one lesion whose longest diameter can be accurately measured as >= . cm with chest x-ray, or as >= . cm with CT scan or MRI scan; or CT component of a PET/CT; NOTE: Disease that is measurable by physical examination only is not eligible; EXCEPTION: Patients with ovarian, fallopian, or peritoneal cancer without measurable disease are eligible if two pretreatment CA values (documented on two occasions taken at least one week apart) are at least twice the upper limit of normal or twice the nadir value if pretreatment CA values never normalized.
Measurable disease, defined as one or more of the following:\r\n* Lymphocytosis >=  in peripheral blood\r\n* Measurable lymph nodes > . cm on palpation and/or computed tomography (CT) scan\r\n* Organomegaly by physical exam and/or CT scan
Measurable disease as defined by the Cheson Response Criteria for Malignant Lymphoma with at least one lesion >= . cm in longest diameter by computed tomography (CT) scan
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a ?. cm lesion, as measured in the longest dimension by computed tomography [CT] scan).
Measurable nodal disease by computed tomography (CT)
Subjects must have measurable lesions (at least one target lesion measuring  cm in diameter) by computerized tomography (CT) scan, and/or measurable lymphoma cutaneous lesions of any size
Must have ?  measurable lesion (? cm in longest dimension) or ?  measurable extranodal lesion (? cm in longest dimension) on computed tomography (CT) scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging by CT (computed tomography) that is at least . cm in the longest diameter and measurable in two perpendicular dimensions as defined by IWG (International Working Group) response criteria for NHL (non-Hodgkin Lymphoma).
Subject with lymphoma who has measurable disease (? . cm in its longest dimension by computed tomography) or chronic lymphocytic leukemia in need of treatment.
At least  measurable (?  cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging that is at least . cm in the longest diameter and measurable in two perpendicular dimensions
Patients must have bi-dimensional measurable disease (measureable disease by computed tomography [CT] scan defined as at least  lesion that measures >=. cm in single dimension); patient with leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) mantle cell lymphoma (MCL), or bone marrow (BM) MCL are also eligible; gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately
Measurable disease sites on CT scan (>. cm in longest dimension)
Patients must have bi-dimensional measurable disease (measurable disease by computed tomography [CT] scan defined as at least  lesion that measures >= . cm in single dimension); patient with leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligible
Measurable disease (at least one lesion that is . cm in the longest diameter on cross?sectional imaging and measurable in  perpendicular dimensions per computed tomography [CT]) for non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) subjects; for myeloma patients measurable disease is defined as presence of more than % plasma cells in the bone marrow aspiration and/or presence of monoclonal gammopathy in serum protein electrophoresis (SPEP) and immunofixation
Participants must have measurable disease (lymphocytosis > ,/ul, or palpable or CT measurable lymphadenopathy > . cm, or bone marrow involvement > %)
Measurable disease with a lymph node or tumor mass > . cm in at least one dimension as assessed by computed tomography (CT)
Measurable disease with a lymph node or tumor mass ?. cm in at least one dimension by CT, PET/CT or MRI.
Patients must have measurable disease per RECIST . by computed tomography (CT) scan or magnetic resonance imaging (MRI); lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >=  cm with CT or MRI (or >= . cm for lymph nodes); index lesions for the purpose of RECIST . measurements will not be selected from within the radiation therapy treatment field; however, if there is evidence of disease progression within the radiation treatment field, measurement of the progressing lesions will be documented
Measurable nodal disease by computed tomography
Measurable disease as assessed by  dimensional measurement by computed tomography (CT) (>  cm or . cm if . cm slices are used, as in spiral CT scan)
Measurable disease defined as: \r\n* At least one non-nodal lesion whose longest diameter can be accurately measured as >= . cm with chest x-ray, or as >= . cm with spiral computed tomography (CT) scan, >=  cm with CT component of a positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); and/or\r\n* A lymph node whose short axis must be > . cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than  mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Histologically confirmed B-cell NHL (FL or DLBCL), transformed indolent lymphoma, and MCL: Measurable disease defined as ?  lesion ?  mm in one dimension or ? mm in  dimensions as measured by conventional or high-resolution (spiral) computed tomography (CT). For Arms C and D: disease evaluable by the International Working Group criteria (Cheson et al, )
Measurable disease as assessed by  dimensional measurements by computed tomography (CT) (>= . cm)
Measurable disease with a lymph node or tumor mass >. cm in at least one dimension as assessed by computed tomography (CT)
Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT)
Patients must have measurable disease on the D planning computed tomography (CT)
Measurable disease on computed tomography (CT) or evaluable disease with an elevated prostate specific antigen (PSA)
At least one measurable lesion ?  cm in longest diameter by CT and/or MRI scan
Patients should have measurable disease defined as a minimum of one tumor measuring >=  mm on computed tomography (CT) scans
? measurable lesion site on CT scan (>. cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)
Measurable or assessable disease defined as at least one of the following:            \r\n* A lymph node or tumor mass that is >= . cm in at least one dimension by computed tomography (CT) portion of positron emission tomography (PET)/CT scan, CT scan, or magnetic resonance imaging (MRI)\r\n* Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
Participants in the Kinetic Studies Arm cannot have non-measurable disease (<  cm) by CT
Measurable disease (>= . cm) as assessed by  dimensional measurement by computed tomography (CT)
For iNHL: measurable nodal disease, defined as the presence of >=  nodal lesion that measures >=  cm in a single dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have measurable disease (. cm or greater) by computed tomography (CT) scan
Criteria , Participants have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than or equal to  cm dimension and for which the longest diameter is greater or equal to  cm as measured by CT (Computed Tomography) scan or magnetic resonance imaging. The metastatic liver lesion(s) must not be in an area that received prior localized therapies.
